BAT1706 vs IBI305

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline

BAT1706 · Avzivi

Marketed by Bio-Thera Solutions and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03329911 · Phase 3 · completed

This double-blind, randomized Phase 3 trial compared BAT1706, a proposed bevacizumab biosimilar, with EU-sourced Avastin, each with paclitaxel and carboplatin, in 651 patients with advanced non-squamous non-small cell lung cancer. The primary endpoint was overall response rate at week 18, tested for equivalence against pre-specified margins (risk ratio 0.75 to 1.33 or 0.73 to 1.36; risk difference -0.12 to 0.15). Both the risk ratio (1.08, 90% CI 0.94 to 1.24) and the risk difference (0.03, 95% CI -0.04 to 0.11) fell inside the margins, so the equivalence primary was met. Source: the peer-reviewed paper (Cancer Med 2023).

Reported efficacy

Overall Response Rate (Week 18): Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023). (met)

Result source: NCT03329911

IBI305

Marketed by Innovent Biologics

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT02954172 · Phase 3 · completed

This was a randomized, double-blind, active-controlled trial with 450 enrolled participants (220 and 221 in the reported primary analysis groups). Its primary clinical endpoint, objective response rate at 18 weeks, met the prespecified equivalence criterion: 44.3% with IBI305 versus 46.4% with bevacizumab, with the 90% confidence interval for the odds ratio entirely within the 0.75–1.33 equivalence margin.

Reported efficacy

Objective Response Rate (18 weeks): Objective response rate at 18 weeks: 44.3% IBI305 (n=221) vs 46.4% bevacizumab (n=220); odds ratio 0.90 (90% CI 0.756–1.077), prespecified equivalence margin 0.75–1.33. (met)

Result source: NCT02954172

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBAT1706IBI305
PFS, median—Not posted · NCT033299118.4 vs 8.3vs Bevacizumabn 221NCT02954172
OS, median—Not posted · NCT0332991118.0n 221NCT02954172
ORR—Not posted · NCT0332991144.3% vs 46.4%vs Bevacizumabwk 18 · n 221NCT02954172
Duration of response, median—Not posted · NCT03329911—Not reported

PFS, median

BAT1706
—Not posted · NCT03329911
IBI305
8.4 vs 8.3vs Bevacizumabn 221NCT02954172

OS, median

BAT1706
—Not posted · NCT03329911
IBI305
18.0n 221NCT02954172

ORR

BAT1706
—Not posted · NCT03329911
IBI305
44.3% vs 46.4%vs Bevacizumabwk 18 · n 221NCT02954172

Duration of response, median

BAT1706
—Not posted · NCT03329911
IBI305
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. BAT1706: 3 of 4 rows · IBI305: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBAT1706IBI305
Dropout rate
31.7%
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
1.3%a
NCT02954172 · Phase 3 · combination
Discontinued due to AEs
—
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—a
NCT02954172 · Phase 3 · combination
Serious AEs
36.6%
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
33.5%a
NCT02954172 · Phase 3 · combination
Most frequent reported AEs
musculoskeletal and connective tissue disorders 1.5%
renal and urinary disorders 0.9%
hepatobiliarydisorders 0.3%
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
a
white blood cell count decreased 71.9%
neutrophil count decreased 70.5%
platelet count decreased 50.4%
NCT02954172 · Phase 3 · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

BAT1706

ORR 44.6% (n=325) vs 47.9% (n=326) EU Avastin® @ 18wk
event count · % of participants
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 · converted to % from 145 Participants as posted

IBI305

ORR 44.3% (n=221) vs 46.4% (n=220) Bevacizumab @ 18wk
responder rate · % of participants
NCT02954172 · Phase 3 · combination
Overall Survival 18.02 vs NA Bevacizumab months
time to event · months
NCT02954172 · Phase 3 · combination
PFS 8.43 vs 8.26 Bevacizumab months
time to event · months
NCT02954172 · Phase 3 · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAT1706's landscape · IBI305's landscape